Vermillion Announces First Quarter 2008 Financial Results and Busines...(veloping PAD. * Further bolstere...)

* Further bolstered Vermillion's intellectual property by advancing

the Company's license agreement with Stanford University to an

exclusive level. The license from Stanford covers the development

and commercialization of a biomarker panel used to assess the risk

of PAD.

* Hosted a roundtable teleconference focusing on Vermillion's PAD

diagnostic program and the need for improved detection of this

life- and limb-threatening condition. The teleconference featured

keynote speaker John Cooke, M.D., Ph.D., Professor of Medicine at

Stanford University, whose research forms the basis of Vermillion's

VASCLIR test.

* Conducted market-development activities, including working with the

PAD Coalition and implementing an online physician survey to gather

market-based information, helping to define the Company's

commercialization strategy and broaden future clinical use of

VASCLIR.

-- Ovarian Cancer Diagnostic Program

* Continued to make progress with the clinical study evaluating OVA1

and plan to submit to the FDA in the second quarter.

* Presented data from several studies demonstrating the benefits of

the Company's ovarian cancer diagnostic test programs at the

Society of Gynecologic Oncologists' (SGO) 39th Annual Meeting on

Women's Cancer. The data suggest that use of Vermillion's tests

could help better identify women with early-stage ovarian cancer

and improve detection.

* Received the distinguished SGO Basic Science Poster Award for its

abstract, "Prospective independent validation of a marker panel for

distinguishing benign from malignant pelvic masses."

-- Hematology Diagnostic Program

* Reporte
'/>"/>